Posted by Michael Wonder on 02 Mar 2025
mRESVIA RSV vaccine approved to protect patients aged 60 and over
28 February 2025 - A study found that around 4 months after vaccination, people who received the respiratory syncytial virus vaccine had a 79% reduction in their risk of getting lower respiratory tract disease caused by RSV, compared with those who received placebo.
The MHRA has approved an mRNA respiratory syncytial virus vaccine (mRESVIA) to protect patients aged 60 and over against lower respiratory tract disease caused by respiratory syncytial virus.
